SMARCD3 and neoplasm: To assess the impact of Smarcd3 deletion directly in the autochthonous KPF model, we tracked tumor emergence by palpation and enrolled CRE+ and CRE− tumor-bearing KPF mice into treatment with tamoxifen followed by tumor analysis three weeks later (Fig. 2h).